Moderna, Inc. officer Stephen Hoge filed a Form 144 notice on November 17, 2026, proposing the sale of 39,215 shares of Moderna common stock through Fidelity Brokerage Services LLC on NASDAQ:MRNA.

Key Highlights

  • Proposed sale: Stephen Hoge, an officer of Moderna, Inc., intends to sell 39,215 shares of common stock with an aggregate market value of $8,298,104.59.
  • Acquisition method: The 39,215 shares were acquired via stock option exercise from the issuer on November 17, 2026, with cash payment on the same date.
  • Shares outstanding: According to the filing, 404,620,975 shares of Moderna common stock were outstanding at the time of the notice.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of June 15, 2026.
  • Prior sales in past 3 months: Hoge reported five prior sales of common stock between September 14, 2026 and November 16, 2026, totaling 198,104 shares with combined gross proceeds of $37,306,871.71.
  • Broker: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is named as the broker for the proposed sale.

Stephen Hoge's Proposed Rule 144 Sale of Moderna Common Stock

According to the Form 144 notice filed with the SEC on November 17, 2026, Moderna, Inc. (NASDAQ:MRNA) officer Stephen Hoge proposed to sell 39,215 shares of the company's common stock at an approximate date of November 17, 2026. The filing lists an aggregate market value of $8,298,104.59 for those shares. The securities were acquired through a stock option exercise from the issuer, with the acquisition and payment both dated November 17, 2026, and the nature of payment listed as cash.

The filing discloses that Hoge relied on a written trading plan under Rule 10b5-1, with a plan adoption date of June 15, 2026. The notice was signed by Gary Redman as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Stephen Hoge. Under the terms of the form, Hoge represented that he does not know any material adverse information regarding the current and prospective operations of Moderna that has not been publicly disclosed, as of the plan adoption date.

The filing also details five sales of Moderna common stock by Hoge during the prior three months. Those transactions occurred on September 14, 2026 (40,294 shares, $5,807,747.48 gross proceeds), September 15, 2026 (40,281 shares, $5,883,708.71), October 14, 2026 (39,224 shares, $8,373,519.91), October 15, 2026 (39,145 shares, $8,640,033.51), and November 16, 2026 (39,160 shares, $8,601,862.10). These prior-period sales are required disclosures under Rule 144 and are reported for aggregation purposes as specified by the form.

What Was Disclosed

Moderna officer Stephen Hoge filed a Form 144 notice proposing to sell 39,215 shares of common stock acquired via stock option exercise, valued at approximately $8,298,104.59, under a Rule 10b5-1 plan adopted on June 15, 2026, with Fidelity Brokerage Services LLC as broker.